Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nebulized Ensifentrine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Arm 1: Ensifentrine | EXPERIMENTAL | - |
| Treatment Arm 2: Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Nebulized Ensifentrine Suspension; 3 mg | DRUG | Administered by a standard jet nebulizer, twice daily up to a maximum of 52 weeks |
| Nebulized Placebo Solution | DRUG | Administered by a standard jet nebulizer, twice daily up to a maximum of 52 weeks |
Inclusion Criteria: * Males are eligible to participate if they agree to use contraception as described in the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication * Females are eligible to participate if they are no...
Nebulized Ensifentrine is an investigational small molecule being developed for the treatment of non-cystic fibrosis bronchiectasis, a chronic respiratory condition. It is administered as a nebulized suspension at a dose of 3 mg. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Nebulized Ensifentrine is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with non-cystic fibrosis bronchiectasis.
Nebulized Ensifentrine is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is actively recruiting participants to assess the treatment for non-cystic fibrosis bronchiectasis.
Nebulized Ensifentrine is being studied in a Phase 2 clinical trial registered as NCT06559150. This randomized, double-blind, placebo-controlled study is recruiting 284 participants with non-cystic fibrosis bronchiectasis across the United States, Italy, Spain, and the United Kingdom. The trial is currently active and enrolling adults aged 18 years and older.
Yes, Nebulized Ensifentrine is also known as Nebulized Ensifentrine Suspension, 3 mg. These names refer to the same investigational drug product being developed by Merck & Company, Inc. for the treatment of non-cystic fibrosis bronchiectasis.